In June 2006 Bayer AG has bought the majority of shares of Schering AG. As a result of this take-over Schering AG has been renamed in December 2006 in Bayer Schering Pharma AG. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group.
Berlex Laboratories (USA) and Berlex Canada Inc., former affiliates of Schering AG, have been integrated into Bayer HealthCare and operate as a specialty pharmaceuticals business that also sells MRIcontrast agents, under the name Bayer HealthCare Pharmaceuticals, which is a subsidiary of Bayer Schering Pharma AG.
The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.
The phase of software testing where a program or system is turned over to a select group of users outside the development organization for use in real-life situations.